← Back to Home

Delivering an oversized gene to the retina in two parts: Atsena reports monkey study results for Usher syndrome

ATSN-301 produced full-length MYO7A protein in nonhuman primate retinas, while a six-month toxicology study provided preliminary safety evidence; whether it can slow vision loss in patients remains a question for human trials.

By SURL BioNews

For patients with Usher syndrome who are born with severe hearing impairment and begin losing vision in childhood, preserving sight is especially urgent. Atsena Therapeutics announced on October 30 that ATSN-301, its gene therapy under development for Usher syndrome type 1B (USH1B), had produced full-length MYO7A protein in nonhuman primate retinas and completed a six-month toxicology study. This is preclinical progress toward human trials and does not yet demonstrate that the treatment can preserve patients’ vision.

Usher syndrome involves hearing and vision impairment, with some types also affecting balance. Patients with type 1 typically have severe to profound hearing loss from birth, while retinitis pigmentosa gradually becomes apparent in childhood; as photoreceptors degenerate, night vision and peripheral vision may be affected first. USH1B is associated with variants in the MYO7A gene, and this study of ATSN-301 focused on delivery to the eye.

The first challenge in replacing MYO7A is vector capacity. Its protein-coding sequence is approximately 6.7 kb, exceeding the roughly 4.8 kb packaging capacity of a single adeno-associated virus (AAV) vector. ATSN-301 therefore splits the gene between two vectors. After both parts enter the same cell, DNA-level recombination and subsequent transcript processing produce a message capable of directing the production of the full-length protein.

Another hurdle is reaching the central retina, which is critical for fine vision. The company said that, using the AAV.SPR capsid capable of lateral spread, researchers performed subretinal injections outside the fovea and still achieved MYO7A expression extending into the macula, without detaching the fovea during surgery. This result supports the delivery design, but a gap remains between getting the protein to the target region and providing long-term protection of vision.

On safety, according to the company’s announcement, the six-month study conducted in compliance with Good Laboratory Practice found no adverse effects at the highest dose tested, nor any treatment-related systemic toxicity or electroretinogram changes. This result defines only the scope of observations under the conditions of this animal study; it cannot directly establish a safe dose for humans or rule out risks that might emerge over a longer period.

Atsena expects to submit an Investigational New Drug application to the U.S. Food and Drug Administration in 2027. The company said the data had been presented at the European Society of Gene and Cell Therapy annual meeting and posted as a preprint; the study details that could be verified for this report still came primarily from the company’s announcement, and the full preprint was not available for review. The next key question is whether this dual-vector design can continue to work in patients’ eyes and translate protein expression into measurable protection of vision.

References

  1. Atsena Therapeutics